Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2018 Dec 21;9(3):510-515.
doi: 10.1159/000495743. eCollection 2018 Sep-Dec.

A 5-Year-Old Case of Choroidal Neovascularization in Enhanced S-Cone Syndrome Treated with Ranibizumab

Federica Bertoli  1   2 , Silvia Pignatto  1 , Francesca Rizzetto  3 , Paolo Lanzetta  1
Affiliations
Case Reports

A 5-Year-Old Case of Choroidal Neovascularization in Enhanced S-Cone Syndrome Treated with Ranibizumab

Federica Bertoli et al. Case Rep Ophthalmol. .

Abstract

Introduction: We describe the youngest case of enhanced S-cone syndrome (ESCS) associated with choroidal neovascularization (CNV) successfully treated with intravitreal ranibizumab injections.

Case report: A 5-year-old boy presented with round-shaped fibrotic subretinal lesions in both eyes with surrounding subretinal fluid and progressive visual deterioration in the right eye. Fine foci of increased autofluorescence were observed along the arcades in both eyes. Fluorescein angiography revealed the presence of CNV in his right eye, and treatment with ranibizumab was initiated, with significant improvement in vision. Subsequent electroretinogram examination and genetic studies of the patient and his two younger siblings confirmed the diagnosis of ESCS.

Conclusion: CNV has been reported to occur in different inherited retinal degenerations, including ESCS. Our experience confirms that treatment with ranibizumab in patients with CNV-complicated ESCS can be potentially vision-saving.

Keywords: Anti-VEGF; Choroidal neovascularization; Electroretinogram; Enhanced S-cone syndrome; NR2E3; Ranibizumab.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Color fundus photography (a), fundus autofluorescence imaging (b), fluorescein angiography (c), and OCT images (d) of the patient in May 2011 (right eye in the upper line, left eye in the lower line).
Fig. 2
Fig. 2
Color fundus photography (a) and OCT images (b) of the patient in the right eye after two ranibizumab injections.
Fig. 3
Fig. 3
Color fundus photography (a) and OCT images (b) of the patient in 2018 (right eye in the upper line, left eye in the lower line).
See this image and copyright information in PMC

References

    1. Hull S, Arno G, Sergouniotis PI, Tiffin P, Borman AD, Chandra A, et al. Clinical and molecular characterization of enhanced S-cone syndrome in children. JAMA Ophthalmol. 2014 Nov;132((11)):1341–9. - PubMed
    1. Milam AH, Rose L, Cideciyan AV, Barakat MR, Tang WX, Gupta N, et al. The nuclear receptor NR2E3 plays a role in human retinal photoreceptor differentiation and degeneration. Proc Natl Acad Sci USA. 2002 Jan;99((1)):473–8. - PMC - PubMed
    1. Schorderet DF, Escher P. NR2E3 mutations in enhanced S-cone sensitivity syndrome (ESCS), Goldmann-Favre syndrome (GFS), clumped pigmentary retinal degeneration (CPRD), and retinitis pigmentosa (RP) Hum Mutat. 2009 Nov;30((11)):1475–85. - PubMed
    1. Sustar M, Perovšek D, Cima I, Stirn-Kranjc B, Hawlina M, Brecelj J. Electroretinography and optical coherence tomography reveal abnormal post-photoreceptoral activity and altered retinal lamination in patients with enhanced S-cone syndrome. Doc Ophthalmol. 2015 Jun;130((3)):165–77. - PubMed
    1. Broadhead GK, Grigg JR, McCluskey P, Korsakova M, Chang AA. Bevacizumab for choroidal neovascularisation in enhanced S-cone syndrome. Doc Ophthalmol. 2016 Oct;133((2)):139–43. - PubMed

Publication types